Intravascular Coagulation and Fibrinolysis by Stapliylocoagiilase. Comparison with Thrombin^[*]

 

 Buy Article Permissions and Reprints

Summary

Intravascular clotting in rabbits after intravenous injection of 30 N.I.H. units of thrombin/kg and 5/mg/kg of staphylocoagulase were studied. Following determinations were made : clotting time, thrombin time, fibrinogen, factors V, VII, VIII, X, XI and XII, “true prothrombin”, two stage prothrombin, P-P test, prothrombin consumption, fibrinolysis in serum euglobulins, plasminogen, antithrombin III and VI, and coagulase reacting factor. Intravenous staphylocoagulase produced in rabbits precipitous drop of fibrinogen level in a very short time, which was not observed with the dose of thrombin used. Activity of staphylocoagulase in vivo was very much higher than of thrombin, as it could be expected on basis of the in vitro comparison. Together with defibrination caused by staphylocoagulase, fibrinogen breakdown products, identified as antithrombin VI, appear in plasma. There were no such changes observed when thrombin was used. Slight decrease of prothrombin and antithrombin III levels, together with a lack of significant changes in factors V, VII, VIII, X, XI and XII content, were observed after staphylocoagulase injection. Slight increase of CRF content in staphylo co agulase clotted plasma was noted. Fibrinolytic system was not activated during clotting process caused by staphylo-coagulase. Significance of the data obtained is discussed.

^* This study was supported by research grant CDC-LP-3 from the Communicable Disease Center, U. S. Public Health Service.

• References

• 1 Astrup T, Mullertz S. The fibrin plate method for estimation fibrinolytic activity. Arch. Biochem. 40: 346 1952;
  CrossrefPubMedGoogle Scholar
• 2 Blobel H, Berman D. T. Further studies on the in vivo activity of staphylocoagulase. J. Infect. Dis. 105: 63 1961;
  PubMedGoogle Scholar
• 3 Budzynski A. Z, Batallo Z, Lipinski B, Kowalski E. The effect of pH on the interaction of the fibrinogen degradation products (FDP) with the fibrinogen-fibrin conversion. Bull. Acad. Polon. Sci., Cl. VI (11) 477 1963;
  PubMedGoogle Scholar
• 4 Drummond M. C, Tag er M. Fibrinogen clotting and fibr ino-peptide formation by staphylocoagulase and the coagulase reacting factor. J. Bacteriol. 85: 628 1963;
  PubMedGoogle Scholar
• 5 Hansen A, Loeliger E. A. Antithrombin III. Its metabolism and its function in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 1: 9 1963;
  PubMedGoogle Scholar
• 6 Haughton G, Duthie E. S. The activation of staphylococcal free coagulase by plasma constituents and the hydrolysis of N^a-toluene-p-sulphonyl-l-arginine methyl ester (TAME) by activated coagulase. Biochem. J. 71: 348 1959;
  CrossrefPubMedGoogle Scholar
• 7 Jeljaszewicz J. Studies on staphylococcal coagulases: II. Purification of free coagulase. Med. Dosw. Mikrobiol. 10: 287 1958;
  PubMedGoogle Scholar
• 8 Jeljaszewicz J. Studies on staphylococcal coagulases: I. Methods for determination of free and bound coagulase. Acta microbiol. pol. 7: 259 1958;
  PubMedGoogle Scholar
• 9 Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (factor VI). Acta haemat. (Basel) 6: 1 1951;
  CrossrefPubMedGoogle Scholar
• 10 Kowalski E, Budzynski A. Z, Kopec M, Batallo Z. S, Lipinski B, Wçgrzynowicz Z. Circulating fibrinogen degradation products in dog blood after intravenous thrombin infusion. Thrombos. Diathes. haemorrh. (Stuttg.) (In press.)
  PubMed
• 11 Kowalski E, Kopec M, Niewiarowski S. Evaluation of the euglobulin method of determination of fibrinolysis. J. clin. Path. 12: 215 1959;
  CrossrefPubMedGoogle Scholar
• 12 Lasch H. G, Rodriguez-Erdmann F. Etude de l’influence du choc sur le système du coagulation dans le phénomène de Sanarelli-Shwartzman. Hémostase 1: 161 1961;
  PubMedGoogle Scholar
• 13 Lasch H. G, Rodriguez-Erdmann F, Schimpf K. Antithrombin III and anti-blutthrombo-kinasebei experimenteller Verbrauchskoagulopathie. Klin. Wschr. 39: 645 1961;
  CrossrefPubMedGoogle Scholar
• 14 Latallo Z. Critical evaluation of the thrombin time test. Proc. Vlllth Congr. E uro p. Soc. Haemat., p. 423. Karger, Basel-N. Y. 1962
  PubMed
• 15 Leonow A. Porównawcze badania protrombiny metodi jednostopniow^ i dwustopniow%. Przegl. Lek. 21: 24 1959;
  PubMedGoogle Scholar
• 16 Lewis J. H, Szeto I. L. Effects of intravenous tissue thromboplastin in dogs: development of an anticoagulant. J. Lab. clin. Med. 60: 261 1962;
  PubMedGoogle Scholar
• 17 Loeb L. The influence of certain bacteria on the coagulation of the blood. J. med. Res. 10: 407 1903;
  PubMedGoogle Scholar
• 18 Miale J. B. Relationship of coagulase-globulin to prothrombin. Proc. Soc. exp. Biol. (N. Y.) 75: 432 1950;
  CrossrefPubMedGoogle Scholar
• 19 Miale J. B. The role of coagulase-globulin in blood coagulation and its thromboplastic action. Amer. J. clin. Path. 22: 218 1952;
  PubMedGoogle Scholar
• 20 Monkhouse F. C, Milojevie S. Changes in fibrinogen level after infusion of thrombin and thromboplastin. Amer. J. Physiol. 199: 1165 1960;
  PubMedGoogle Scholar
• 21 Niewiarowski S. L’adsorption des facteurs du système fìbrinolytique par la bentonite. Path. Biol. (Paris) 7: 2557 1959;
  PubMedGoogle Scholar
• 22 Niewiarowski S, Kowalski E. Un nouvel anticoagulant dérivé du fibrinogène. Rev. Hémat. 13: 320 1958;
  PubMedGoogle Scholar
• 23 Niewiarowski S, Zywicka H, Latallo Z. Coagulation disorders in thrombocythaemia. A study of seven cases. Thrombos. Diathes. haemorrh. (Stuttg.) 7: 114 1962;
  PubMedGoogle Scholar
• 24 Owren P. A, Aas K. The control of dicumarol therapy and the quantitative determinations of prothrombin and proconvertin. Sc and. J. clin. Lab. Invest. 3: 201 1951;
  PubMedGoogle Scholar
• 25 Quick A. J. Hemorrhagic Diseases. Lea and Fibiger; Philadelphia: 1957
  Google Scholar
• 26 Quick A. J, Hussey G. V, Harris J, Peters K. Occult intravascular clotting by means of intravenous injection of thrombin. Amer. J. Physiol. 197: 791 1959;
  PubMedGoogle Scholar
• 27 Rubinstein M. H. Studies on the mechanism of action of staphylocoagulase. Brit. J. Haematol. 4: 326 1958;
  CrossrefPubMedGoogle Scholar
• 28 Schimpf K, Gibelins A, Marclini R. Die physiologischen Inhibitoren der Blutgerinnung bei pathologisch gesteigerter Gerinnbarkeit in vivo. Klin. Wschr. 42: 637 1964;
  CrossrefPubMedGoogle Scholar
• 29 Schröer H, Hauck G, Peiper U. Auswirkungen experimentell erzeugter schwerer Gerinnungsdefekte des Blutes in vivo. Thrombos. Diathes. haemorrh. (Stuttg.) 7: 538 1962;
  PubMedGoogle Scholar
• 30 Smith D. D, Johnstone J. M. Staphylocoagulase activity in vivo. Brit. J. exp. Path. 38: 165 1958;
  PubMedGoogle Scholar
• 31 Soulier J. P, Barrien M. J. Étude analytique des temps de Quick allongés. Dosage de prothrombine, de proconvertine et de proaccelerine. Sang 23: 549 1952;
  PubMedGoogle Scholar
• 32 Soulier J. P, Larrieu M. J. Nouvelle méthode de diagnostic de l’hémophilie. Dosage des facteurs antihemophiliques A et B. Sang 24: 205 1953;
  PubMedGoogle Scholar
• 33 Tager M. Problems in coagulation of plasma by staphylocoagulase. Ann. N.Y. Acad. Sci. 65: 109 1956;
  CrossrefPubMedGoogle Scholar
• 34 Tager M. Studies on the nature and the purification of the coagulase reacting factor and its relation to prothrombin. J. exper. Med. 104: 675 1956;
  CrossrefPubMedGoogle Scholar
• 35 Ware A. G, Seegers W. H. Two stage procedure for the quantitative determination of prothrombin concentration. Amer. J. clin. Path. 19: 471 1949;
  PubMedGoogle Scholar
• 36 Wolf P. A modification for routine laboratory use of Stefanini’s method for estimation of factor V in human oxalatecl plasma. J. clin. Path. 6: 34 1953;
  CrossrefPubMedGoogle Scholar
• 37 Worowski K, Niewiarowski S, Prokopowicz J. Fibrinolysis and fibrinogen breakdown products (antithrombin VI) in renal venous blood (RVB) in dog. Thrombos. Diathes. haemorrh. (Stuttg.). 12: 87 1964;
  PubMedGoogle Scholar